首页> 外文期刊>Journal of the American Veterinary Medical Association >Evaluation of use of human albumin in critically ill dogs: 73 cases (2003-2006).
【24h】

Evaluation of use of human albumin in critically ill dogs: 73 cases (2003-2006).

机译:在危重犬中使用人白蛋白的评估:73例(2003-2006年)。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: To evaluate the use of human albumin in critically ill dogs. Design-Retrospective case series. ANIMALS: 73 client-owned hospitalized dogs. PROCEDURES: Medical records of dogs that received human albumin were reviewed to assess effects of the use of human albumin on serum albumin concentration, colloid osmotic pressure, and total protein concentration; determine the relationships between these variables and outcome; and assess its safety. Data for signalment, diagnoses, physiologic variables, dosage, amount of crystalloid fluid administered prior to human albumin administration, complications, and outcome were reviewed. Additionally, pre- and postadministration values for serum albumin, colloid osmotic pressure, and total protein were recorded. RESULTS: Administration of human albumin resulted in significant changes in serum albumin, colloid osmotic pressure, and total protein. The serum albumin, total protein, degree of improvement in serum albumin, colloid osmotic pressure, and dosage of human albumin were significantly greater in survivors. Seventeen of 73 (23%) dogs had at least 1 complication that could be potentially associated with the administration of human albumin that occurred during or immediately following administration of human albumin. Three of 73 (4%) dogs had severe delayed complications. CONCLUSIONS AND CLINICAL RELEVANCE: Administration of human albumin significantly increased serum albumin, and total protein concentrations and colloid osmotic pressure, especially in survivors. Because of the high mortality rate of the study population and other confounding factors, it was uncertain whether complications were associated with the underlying disease or with human albumin administration. Acute and delayed complications may have been under-recognized.
机译:目的:评估人白蛋白在危重犬中的使用。设计回顾案例系列。动物:73只客户拥有的住院狗。程序:审查接受人白蛋白的狗的病历,以评估使用人白蛋白对血清白蛋白浓度,胶体渗透压和总蛋白浓度的影响;确定这些变量与结果之间的关系;并评估其安全性。审查了有关信号,诊断,生理变量,剂量,在施用人白蛋白之前所施用的结晶液量,并发症和结局的数据。另外,记录给药前和给药后的血清白蛋白,胶体渗透压和总蛋白值。结果:人白蛋白的施用导致血清白蛋白,胶体渗透压和总蛋白的显着变化。幸存者的血清白蛋白,总蛋白,血清白蛋白改善程度,胶体渗透压和人白蛋白剂量明显更高。 73只狗中有17只(23%)患有至少1种并发症,可能与施用人白蛋白期间或之后发生的施用人白蛋白有关。 73只狗中有3只(4%)具有严重的延迟并发症。结论和临床意义:人白蛋白的施用显着增加了血清白蛋白,总蛋白浓度和胶体渗透压,特别是在幸存者中。由于研究人群的高死亡率和其他混杂因素,因此不确定并发症是否与潜在疾病或人类白蛋白管理有关。急性和迟发性并发症可能未得到充分认识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号